3 doses of mRNA COVID vaccine show advantage against severe outcomes The authors said COVID-19 infection can result in a "brainstem insult" that results in clusters of physical long-COVID symptoms. CIDRAP

A team led by US Food and Drug Administration (FDA) researchers studying Medicare claims data during the early Omicron SARS-CoV-2 variant months conclude that a third dose of mRNA COVID-19 vaccine provides significant protection against hospitalization and death compared with two doses but wanes substantially after 4 months.

...

Novavax gets EU authorization for updated COVID vaccine targeting JN.1 strain

The European Commission authorized Novavax's (NVAX.O)

Only 45% of Americans age 50 and older say they're likely to get the updated COVID-19 vaccine this season, according to a poll today from the University of Michigan. 

The poll shows many at high risk of severe illness appear unlikely to seek the vaccine, and interest in an updated vaccine varies widely by age-group, education level, and other factors.

The results come from the National Poll on Healthy Aging conducted in August. At the time of polling, new COVID vaccines were not yet widely available, but they had been approved for use and endorsed by the Centers for Disease Control and Prevention. 

...